A multi-center, open-label study evaluating the efficacy and safety of Rituxan [rituximab] in combination with cyclophosphamide/doxorubicin, vincristine and prednisone chemotherapy following by Rituxan maintenance as initial therapy for patients with aggressive non-Hodgkin's lymphoma

Trial Profile

A multi-center, open-label study evaluating the efficacy and safety of Rituxan [rituximab] in combination with cyclophosphamide/doxorubicin, vincristine and prednisone chemotherapy following by Rituxan maintenance as initial therapy for patients with aggressive non-Hodgkin's lymphoma

Not stated
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Dec 2005

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top